Press Releases - 2022-03-31

Date	Title	Company
31-Mar-2022	Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design	Iktos
31-Mar-2022	Novartis UK response to NICE Appraisal Consultation Document (ACD) for Piqray (alpelisib) for advanced breast cancer patients	Novartis
31-Mar-2022	Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement (news with additional features)	Vivoryon Therapeutics N.V.
31-Mar-2022	Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH)	M1 Kliniken AG
31-Mar-2022	Avance Clinical Announces New Office Opening in Melbourne	Avance Clinical
31-Mar-2022	Immutep’s efti in combination with MSD’s pembrolizumab shows encouraging antitumor activity in difficult to treat second line metastatic lung cancer patients	Immutep Limited
31-Mar-2022	Fitabeo Therapeutics shortlisted for National StartUp Award	Fitabeo Therapeutics
31-Mar-2022	Solvay Brussels School of Economics and Management joins forces with the Belgian life sciences ecosystem to train the next generation of Biotech and MedTech leaders	Solvay Brussels School of Economics and Management
31-Mar-2022	TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer	TILT Biotherapeutics
31-Mar-2022	V-Bio Ventures raises EUR 110 million for its second fund and expands team	V-Bio Ventures
31-Mar-2022	Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines	Sanofi
31-Mar-2022	Pharma Business Development: In-person Format Clearly Beats Video Conferencing	RauCon GmbH & Co. KG
31-Mar-2022	Maruho Deutschland GmbH: Statement of Maruho Deutschland GmbH on the proposed capital measures in the context of the Extraordinary General Meeting on 7 April 2022	Maruho Deutschland GmbH
31-Mar-2022	Körber wins two awards at the Asia-Pacific Bioprocessing Excellence Awards for its state-of-the-art solutions for life sciences industry	Körber
31-Mar-2022	Turnaround in FY/2021: Significant sales growth (+30%) and substantially improved EBIDTA (+84%) - clear trend towards black zero	aap Implantate AG
31-Mar-2022	Relief Reports Full-Year 2021 Results and Provides Corporate Update	Relief Therapeutics Holding SA
31-Mar-2022	AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million	AEVIS VICTORIA SA